Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(9 sites)
China
Chinese PLA General Hospital, Beijing, Beijing Municipality The First Affiliated Hospital Of Xiamen University, Xiamen, Fujian The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong Henan Cancer Hospital, Zhengzhou, Henan The First Hospital of China Medical University, Shenyang, Liaoning Liaoning Cancer Hospital, Shenyang, Liaoning Shanxi Cancer Hospital, Taiyuan, Shanxi The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang